Synopsis
Synopsis
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Carbidopa, (r)-isomer
2. Carbidopa, (s)-isomer
3. Lodosin
4. Lodosyn
5. Methyldopahydrazine
6. Mk 485
7. Mk 486
8. Mk-485
9. Mk-486
10. Mk485
11. Mk486
1. 28860-95-9
2. Lodosyn
3. Carbidopa Anhydrous
4. (s)-(-)-carbidopa
5. (s)-carbidopa
6. S-(-)-carbidopa
7. Alpha-methyldopahydrazine
8. L-alpha-methyldopahydrazine
9. N-aminomethyldopa
10. Carbidopum
11. Carbidopum [inn-latin]
12. Carbidopa (anhydrous)
13. S(-)-carbidopa
14. Mk 486
15. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic Acid
16. Carbidopa [inn]
17. L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic Acid
18. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic Acid
19. (-)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic Acid
20. (s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic Acid
21. Kr87b45rgh
22. (alphas)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic Acid
23. Chebi:39585
24. 28860-95-9 (anhydrous)
25. Ncgc00024596-05
26. Hadrazino-alpha-methyldopa
27. C-dopa
28. 3,3,3-trideuterio-2-[dideuterio-(3,4-dihydroxyphenyl)methyl]-2-hydrazinylpropanoic Acid
29. Smr000058235
30. Ccris 5093
31. Sr-01000597655
32. Einecs 249-271-9
33. Unii-kr87b45rgh
34. Benzenepropanoic Acid, .alpha.-hydrazino-3,4-dihydroxy-.alpha.-methyl-, (s)-
35. Alpha-hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic Acid
36. L-alpha-methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic Acid
37. L-alpha-methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic Acid
38. Mfcd00069231
39. Nd0611
40. Tocris-0455
41. C-126
42. Dsstox_cid_2735
43. Carbidopa [who-dd]
44. Dsstox_rid_76707
45. Dsstox_gsid_22735
46. Lopac0_000382
47. Schembl35084
48. Mls000069628
49. Mls002207014
50. S-(-)-carbidopa Monohydrate
51. Gtpl5159
52. Carbidopa, L- Anhydrous
53. Carbidopa Anhydrous [mi]
54. Chembl1201236
55. Dtxsid4022735
56. Hms2089b12
57. Hms3266a20
58. Hms3411m13
59. Hms3655g20
60. Hms3675m13
61. Hms3713l10
62. Hms3884m14
63. Hy-b0311
64. Tox21_110910
65. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methyl-propanoic Acid
66. Bdbm50418773
67. Nsc751137
68. S1891
69. Zinc19168887
70. Akos015969657
71. Benzenepropanoic Acid, Alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, (s)-
72. Hydrocinnamic Acid, Alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, L-
73. Ac-1676
74. Ccg-204476
75. Db00190
76. Sdccgmls-0072919.p025
77. Mls-0072919
78. Smp1_000057
79. Ncgc00024596-01
80. Ncgc00024596-03
81. Ncgc00024596-06
82. Ncgc00024596-07
83. Ncgc00024596-08
84. As-16862
85. Bc164279
86. Mls-0072919.p013
87. Cas-28860-95-9
88. Eu-0100382
89. Sw199080-2
90. 60c959
91. Ab00441332-05
92. Ab00441332-06
93. Ab00441332_07
94. Ab00441332_08
95. Sr-01000597655-1
96. Sr-01000597655-3
97. Sr-01000597655-5
98. Sr-01000597655-9
99. Brd-k78712176-001-07-5
100. Benzenepropanoic Acid, A-hydrazino-3,4-dihydroxy-a-methyl-
101. (-)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinamic Acid
102. (s)-?-hydrazino-?-methyl-?-(3,4-dihydroxyphenyl)propionic Acid
103. (s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropionic Acid
104. (s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoicacid
105. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl-propanoic Acid
106. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropionic Acid Monohydrate
107. Benzenepropanoic Acid, .alpha.-hydrazinyl-3,4-dihydroxy-.alpha.-methyl-, (.alpha.s)-
108. Kinson; 3-(3,4-dihydroxy-phenyl)-2-hydrazino-2-methyl-propionic Acid
109. 1426847-87-1
Molecular Weight | 226.23 g/mol |
---|---|
Molecular Formula | C10H14N2O4 |
XLogP3 | -2.2 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 226.09535693 g/mol |
Monoisotopic Mass | 226.09535693 g/mol |
Topological Polar Surface Area | 116 Ų |
Heavy Atom Count | 16 |
Formal Charge | 0 |
Complexity | 261 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Carbidopa |
PubMed Health | Carbidopa (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | Carbidopa and levodopa extended release tablets are extended release combination of carbidopa and levodopa for the treatment of Parkinsons disease and syndrome.Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline... |
Active Ingredient | Carbidopa |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg |
Market Status | Prescription |
Company | Amerigen Pharms |
2 of 4 | |
---|---|
Drug Name | Lodosyn |
PubMed Health | Carbidopa (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as ()-L--hydrazino--methyl--(3,4-dihydroxybenzene) pro... |
Active Ingredient | Carbidopa |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg |
Market Status | Prescription |
Company | Aton |
3 of 4 | |
---|---|
Drug Name | Carbidopa |
PubMed Health | Carbidopa (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | Carbidopa and levodopa extended release tablets are extended release combination of carbidopa and levodopa for the treatment of Parkinsons disease and syndrome.Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline... |
Active Ingredient | Carbidopa |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg |
Market Status | Prescription |
Company | Amerigen Pharms |
4 of 4 | |
---|---|
Drug Name | Lodosyn |
PubMed Health | Carbidopa (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as ()-L--hydrazino--methyl--(3,4-dihydroxybenzene) pro... |
Active Ingredient | Carbidopa |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg |
Market Status | Prescription |
Company | Aton |
Carbidopa is indicated with [levodopa] for the treatment of symptoms of idiopathic Parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication. The combination therapy is administered for the reduction of [levodopa]-driven nausea and vomiting. The product of carbidopa should be used in patients where the combination therapy of carbidopa/[levodopa] provide less than the adequate daily dosage. As well carbidopa can be used in patients where the dosages of carbidopa and [levodopa] require individual titration.
FDA Label